#Japan #Tokyo #Home Cardio Dock #Kokoromil #eclat

Kokoromil's Central Monitoring System Development

Kokoromil Inc., headquartered in Shinjuku, Tokyo and led by CEO Daiki Hayashi, is revolutionizing cardiac health monitoring with their innovative Home Cardio Dock® technology. Their mission, "Creating a society free from the regret of illness," drives them to prioritize early detection of heart diseases through extended at-home electrocardiogram (ECG) tests. Recently, Kokoromil’s central monitoring system development has been recognized and funded by the Tokyo Small Business Promotion Public Corporation through the 20th Medical Device Industry Entry Promotion Grant Program.

The company plans to launch a fully disposable Holter ECG monitor named "eclat" in 2024, designed for medical institutions to allow continuous monitoring for up to seven days. This groundbreaking device, alongside their ECG analysis software (SaMD), will enhance the efficacy of heart disease prevention. Kokoromil has also emphasized the importance of collecting big data related to ECG through analytical support services and collaborative research initiatives, further laying the groundwork for their new central monitoring system.

This project represents a significant step forward in Kokoromil's capabilities, which will soon enter full-scale development. The goal is to equip individuals and their families with tools to visualize their health status, thereby fostering a longer, healthier life and improving their quality of life (QOL).

Overview of the Home Cardio Dock®

The Home Cardio Dock® is an innovative solution that enables users to undergo extensive ECG testing by simply attaching a palm-sized ECG device to their chest. These devices can take ECG data for over nine hours, ensuring thorough data collection. Trained clinical laboratory technicians then analyze this data to generate comprehensive reports. Since this is a medical device, users can enjoy an examination comparable to hospital standards with relative ease.

This prolonged ECG measurement captures potential hidden cardiac risks that short health screenings, usually limited to about 15 seconds, may miss. Additionally, it helps to visualize sleep quality and stress levels, detecting possible risks for conditions such as sleep apnea, leading to proactive health management.

Pricing for the Home Cardio Dock® starts at 12,100 JPY (including tax), while the advanced version, Home Cardio Dock® PRO, is offered at 19,800 JPY.

Features of eclat

Kokoromil has also developed the eclat, a disposable Holter ECG monitor designed for continuous testing over a period of seven days. This innovation stemmed from feedback in the medical community, indicating that a standard 24-hour test is insufficient to identify sporadic arrhythmias. By utilizing a disposable model, healthcare providers can significantly reduce management costs and minimize risks of device loss. For patients, it means fewer hospital visits and a more streamlined testing process.

Coverage for eclat will become available under insurance starting November 1, 2024, expanding access for many who require comprehensive heart monitoring.

About Kokoromil

Kokoromil Inc. was founded in November 2021, with a vision focused on health care and clinical research projects. Through their innovations, including the Home Cardio Dock®, they aim to visualize health conditions for individuals and families, promoting an improved quality of life and longer health spans.

• - CEO: Daiki Hayashi
• - Location: 2F Kanno Building, 6-2-16 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023
• - Website: Kokoromil

In conclusion, Kokoromil’s dedication to enhancing cardiac health monitoring is setting new standards in the industry, equipped with cutting-edge technology and a commitment to personal health improvement.